Share
Other content recommended for you
- Clinical research on COVID-19: perceptions and barriers to participation in The Gambia
- Are patients with amyotrophic lateral sclerosis at risk of a therapeutic misconception?
- Is it ethical to keep interim findings of randomised controlled trials confidential?
- Informed consent in clinical research in France: assessment and factors associated with therapeutic misconception
- Should desperate volunteers be included in randomised controlled trials?
- Randomised placebo-controlled trials of surgery: ethical analysis and guidelines
- Simplified consent in cluster randomised trials: the new EU Clinical Trials Regulation does not provide sufficient guidance
- Understanding, interests and informed consent: a reply to Sreenivasan
- The ethics of randomised controlled trials from the perspectives of patients, the public, and healthcare professionals
- Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study